DCP作为肝细胞癌经动脉化疗栓塞术疗效的生物标志物。
DCP as a biomarker for TACE efficacy in hepatocellular carcinoma.
作者信息
Xie Hui, Li Youwei, Yang Jie, Tan Yuwei, Xu Jin, Yang Xiao
机构信息
Hepatobiliary Pancreatic Surgery, Deyang People's Hospital, Deyang, Sichuan, China.
出版信息
Front Oncol. 2025 Jul 28;15:1560210. doi: 10.3389/fonc.2025.1560210. eCollection 2025.
INTRODUCTION
Primary hepatocellular carcinoma (PHC) requires advanced diagnostic and therapeutic strategies. While transcatheter arterial chemoembolization (TACE) is a cornerstone treatment, efficacy assessment remains challenging.
METHODS
We retrospectively analyzed 90 PHC patients treated with TACE. Serum DCP levels were measured pre-treatment and at 1, 4, and 8 weeks post-treatment. Treatment response was evaluated using mRECIST criteria.
RESULTS
Low DCP patients (≤40 mAU/mL) showed significantly higher response rates (53.3%) compared to high DCP (>300 mAU/mL, 30.0%, p<0.05). The hazard ratio for treatment failure was 1.62 (95% CI: 1.09-2.23, p<0.01) per unit increase in log-transformed DCP. Median overall survival was 24.5 months for low DCP versus 12.6 months for high DCP patients (log-rank p<0.001).
DISCUSSION
DCP serves as a robust biomarker for predicting TACE efficacy, enabling personalized treatment strategies in PHC management.
引言
原发性肝细胞癌（PHC）需要先进的诊断和治疗策略。虽然经动脉化疗栓塞术（TACE）是一种基石性治疗方法，但疗效评估仍然具有挑战性。
方法
我们回顾性分析了90例接受TACE治疗的PHC患者。在治疗前以及治疗后1周、4周和8周测量血清DCP水平。使用mRECIST标准评估治疗反应。
结果
低DCP患者（≤40 mAU/mL）的反应率（53.3%）显著高于高DCP患者（>300 mAU/mL，30.0%，p<0.05）。经对数转换的DCP每增加一个单位，治疗失败的风险比为1.62（95%CI：1.09-2.23，p<0.01）。低DCP患者的中位总生存期为24.5个月，而高DCP患者为12.6个月（对数秩检验p<0.001）。
讨论
DCP可作为预测TACE疗效的有力生物标志物，有助于在PHC管理中制定个性化治疗策略。
Zotero 插件